Current clinical decision-making for BC treatment relies on tumor characteristics and therapeutic targets including the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and neoplasm.